does hims offer tirzepatide stock plunges as Lilly's Zepbound weight-loss drug shortage ends Tirzepatide $125/mo Compounded (vs $1,069

Konofagou EE, Luo J, Saluja D, et al

Demonstration that exendin-4 is an agonist and exendin-(939) an antagonist of the receptor

Warmth alone is not an absolute contraindication to continued treatment, but it warrants closer observation during the next injection cycle

However, understanding their place in therapy may prove confusing for many primary care practitioners, especially given the common belief that injectables are a last-resort treatment option, which puts them at risk of being niched alongside insulin

Topline results announced in December 2025 were positive, showing that patients who switched from injectables to oral orforglipron maintained their weight loss